Pharma News

ردود أفعال واسعة على حملة “اليوم السابع”

ردود أفعال واسعة على حملة "اليوم السابع".. اللحوم المصنعة أخطر من الخمرة والسجائر.. المعهد القومى للتغذية: تحتوى على مواد مسرطنة وملح البارود.. والأطباء: تزيد إصابة الأطفال بالسكر والسرطان - خبراء ينصحون بمشروب سحرى لإزالة السموم من الجسم يشمل القرفة والزنجبيل والجزر...

read more
Monthly News Roundup – October 2016

Monthly News Roundup – October 2016

Merck’s Zinplava Approved to Fend Off Return of Clostridium Difficile Zinplava (bezlotoxumab) has been FDA-approved to reduce the recurrence of Clostridium difficile infection (CDI) in adults who are receiving antibacterial drug treatment for CDI and who are at high...

read more

First Automated Insulin Delivery Device Gets FDA Approval

The FDA has just approved the first automated insulin delivery device for patients 14 years and older with type 1 diabetes (T1D). Medtronic’s MiniMed 670G hybrid closed looped system, often referred to as an artificial pancreas, serves as an automatic glucose monitor...

read more

FDA Approves Invokamet XR

RARITAN, N.J., September 21, 2016 – Janssen Pharmaceuticals, Inc. (Janssen) announced today the U.S. Food and Drug Administration (FDA) has approved Invokamet XR - a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride...

read more
Quality Risk Management

Quality Risk Management

Regardless of whether you are a member of a quality assurance department in the pharmaceutical industry or not, the term quality risk management (QRM) is likely familiar to you. This is because QRM, a systematic process that assesses risk to the quality of a drug...

read more
All you need to know about medicines and drugs

All you need to know about medicines and drugs

Find out what you are taking with the “British Medical Association Concize Guide to the Medicines & Drugs”. Easy to read, it gives you all the vital information you need to know on today’s most common drugs. The book is divided into three parts. The first part is...

read more

AstraZeneca pulls application for ovarian cancer drug

AstraZeneca is pulling back its application to market ovarian cancer drug cediranib in Europe, marking the end of the line for the drug in combination was chemotherapy. The firm was seeking approval for use of its oral VEGFR inhibitor in combination with...

read more
Gilead pulls plug on ulcerative colitis drug

Gilead pulls plug on ulcerative colitis drug

Gilead Sciences has pulled the plug on a combined Phase II/III clinical study of GS-5745 testing the investigational anti-MMP9 antibody in patients with moderately to severely active ulcerative colitis. The decision follows a planned interim analysis of unblinded...

read more

FDA expands its authority over tobacco products

According to FDA and other sources, tobacco use is the single largest preventable cause of disease and death in the United States. Ned MilenkovichAs part of its goal to improve public health and protect future generations from tobacco use risk, the FDA has engaged in...

read more
UN signs historic declaration to fight AMR

UN signs historic declaration to fight AMR

A historic declaration to combat antimicrobial resistance has been signed by 193 countries at a United Nations General Assembly. Each signatory has agreed that drug resistant infections must be tackled as a priority, in light of projections that, by 2050, 10 million...

read more
Sanofi sues Merck for infringing Lantus patents

Sanofi sues Merck for infringing Lantus patents

Sanofi is taking Merck & Co to court claiming that the firm has infringed 10 patents covering its best-selling insulin glargine products Lantus and Lantus SoloStar. The French drugmaker said it has filed a patent infringement suit against Merck in the US District...

read more
New lifestyle diseases propel high growth of pharma market

New lifestyle diseases propel high growth of pharma market

RIYADH: A significant rise in lifestyle-related diseases and the developments in health care infrastructure will influence the demand for pharmaceuticals in Saudi Arabia that will reach about SR19.5 billion this year in cumulative cost. This will represent a growth of...

read more

ARAB WORLD: OPPORTUNITIES AND RISKS FOR PHARMA

The three primary criteria for a pharmaceutical company to investigate when building a marketing strategy are market size and growth, protection of intellectual property rights and enforcement of said rights. This report provides an insight into these criteria as they...

read more